Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma

Abstract

Alveolar soft part sarcoma is a rare tumour of unknown histogenesis. Although tumour growth is slow and often asymptomatic, vascular invasion and metastatic dissemination (especially to the brain and lung) take place early in the course of disease. Resection is the treatment of choice and could lead to complete remission. If complete resection is not possible, the prognosis of alveolar soft part sarcoma is poor, since conventional cytotoxic chemotherapy regimens have little efficacy in most patients. 1 Reichardt P Lindner T Pink D et al. Chemotherapy in alveolar soft part sarcomas. What do we know?. Eur J Cancer. 2003; 39: 1511-1516 Summary Full Text Full Text PDF PubMed Scopus (102) Google Scholar Therefore, alternative treatment approaches are needed. We report tumour regression in a patient with disseminated alveolar soft part sarcoma during antiangiogenic treatment with the antibody against vascular endothelial growth factor (VEGF), bevacizumab. ErrataAzizi AA, Haberler C, Czech T, et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006; 7: 521–23. In this Case Report, the first sentence of the fifth paragraph (p 522) should have read: “Restaging in October, 2004, revealed progression of the 15 known lesions as well as 12 new pulmonary lesions (figure 2A,C)”. Full-Text PDF